Preventing Adverse Drug Events with Rounding Pharmacists Adverse Drug Events Involving COX-2 Inhibitors Psoriasis Associated with Rofecoxib Adverse Events Seen with Ribavirn Therapy for SARS Immediate Hypersensitivity to Clavulanic Acid Thrombocytopenia with Vancomycin
Restricted accessOtherFirst published online December, 2003
Preventing Adverse Drug Events with Rounding Pharmacists Adverse Drug Events Involving COX-2 Inhibitors Psoriasis Associated with Rofecoxib Adverse Events Seen with Ribavirn Therapy for SARS Immediate Hypersensitivity to Clavulanic Acid Thrombocytopenia with Vancomycin
The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), to discuss methods of prevention, and to promote reporting of ADRs to the FDA's medWatch program (800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers.
Get full access to this article
View all access options for this article.
References
1.
KucukarslanS.N., PetersM., MlynarekM.Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Int Med.2003; 163: 2014–18.
2.
LeapeL.L., CullenD.J., ClappM.D.Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA.1999; 282: 267–70.
3.
VerricoM.M., WeberR.J., McKaveneyT.P.Adverse drug events involving COX-2 inhibitors. Ann Pharmacother.2003; 37: 1203–13.
4.
ClarkD.W.J., CoulterD.M.Psoriasis associated with rofecoxib [letter]. Arch Dermatol.2003; 139: 1223.
5.
KnowlesS.R., PhillipsE.J., DresserL.Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clinical Infectious Diseases.2003; 37: 1139–42.
6.
Raison-PeyronN., MessaadD., BousquetJ.Selective immediate hyper-sensitivity to clavulanic acid [letter]. Ann Pharmacother.2003; 37: 1146–7.
7.
MarraffaJ., GuharoyR., DugganD.Vancomycin-induced thrombocytopenia: A case proven with rechallenge. Pharmacotherapy.2003; 23: 1195–8.
